Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary
The DOI matches its Crossref record; 299 of the 300 references it cites were found in a registry or an index.
Abstract
Abbreviations: A1C = hemoglobin A1C; AACE = American Association of Clinical Endocrinologists; ABCD = adiposity-based chronic disease; ACCORD = Action to Control Cardiovascular Risk in Diabetes; ACCORD BP = Action to Control Cardiovascular Risk in Diabetes Blood Pressure; ACE = American College of Endocrinology; ACEI = angiotensin-converting enzyme inhibitor; AGI = alpha-glucosidase inhibitor; apo B = apolipoprotein B; ARB = angiotensin II receptor blocker; ASCVD = atherosclerotic cardiovascular disease; BAS = bile acid sequestrant; BMI = body mass index; BP = blood pressure; CCB = calcium channel blocker; CGM = continuous glucose monitoring; CHD = coronary heart disease; CKD = chronic kidney disease; DKA = diabetic ketoacidosis; DPP4 = dipeptidyl peptidase 4; eGFR = estimated glomerular filtration rate; EPA = eicosapentaenoic acid; ER = extended release; FDA = Food and Drug Administration; GLP1 = glucagon-like peptide 1; HDL-C = high-density-lipoprotein cholesterol; HeFH = heterozygous familial hypercholesterolemia; LDL-C = low-density-lipoprotein cholesterol; LDL-P = low-density-lipoprotein particle; Look AHEAD = Look Action for Health in Diabetes; NPH = neutral protamine Hagedorn; OSA = obstructive sleep apnea; PCSK9 = proprotein convertase subtilisin-kexin type 9 serine protease; RCT = randomized controlled trial; SU = sulfonylurea; SGLT2 = sodium-glucose cotransporter 2; SMBG = self-monitoring of blood glucose; T2D = type 2 diabetes; TZD = thiazolidinedione.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Epidemiologic evidence shows a continuous relationship between A1C and CVD and all-cause mortality.72”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [72]
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
James, P. A., Oparil, S., Carter, B. L., Cushman, W. C., Dennison-Himmelfarb, C., Handler, J., Lackland, D. T., LeFevre, M. L., MacKenzie, T. D., Ogedegbe, O., et al. (2014) · JAMA · doi:10.1001/jama.2013.284427 · Cited by 7,950
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Cited by
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
Trends in diabetes treatment and control in U.S. adults, 1999-2018
Fang, M., Wang, D., Coresh, J., & Selvin, E. (2021) · New England Journal of Medicine · doi:10.1056/nejmsa2032271 · Cited by 690
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Self-citationSamson, S. L., Vellanki, P., Blonde, L., Christofides, E. A., Galindo, R. J., Hirsch, I. B., Isaacs, S. D., Izuora, K. E., Low Wang, C. C., Twining, C. L., et al. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.02.001 · Cited by 375
Self-citationGLP-1 receptor agonists: an updated review of head-to-head clinical studies
Trujillo, J. M., Nuffer, W., & Smith, B. A. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821997320 · Cited by 289
“0 mg QW 60/299 (20) 29/299 (10) 53/299 (18) 8/299 (3) 20”
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Mokrysheva, N. G., Vikulova, O. K., Galstyan, G. R., Kuraeva, T. L., Peterkova, V. A., Smirnova, O. M., Starostina, E. G., et al. (2022) · Diabetes mellitus · doi:10.14341/dm12802 · Cited by 207
Dedov, I., Shestakova, M., Mayorov, A., Mokrysheva, N., Andreeva, E., Bezlepkina, O., Peterkova, V., Artemova, E., Bardiugov, P., Beshlieva, D., et al. (2023) · Diabetes mellitus · doi:10.14341/dm13042 · Cited by 214
Handelsman, Y., Jellinger, P. S., Guerin, C. K., Bloomgarden, Z. T., Brinton, E. A., Budoff, M. J., Davidson, M. H., Einhorn, D., Fazio, S., Fonseca, V. A., et al. (2020) · Endocrine Practice · doi:10.4158/cs-2020-0490 · Cited by 248
“However, in view of the demonstrated benefits of statin therapy for prevention of ASCVD, the leading cause of death in patients with diabetes, the risk for new onset diabetes or modest worsening of glycemic control in established diabetes does not justify withholding statins in patients with significant ASCVD risk (88…”
Self-citationOxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes
Charlton, A., Garzarella, J., Jandeleit-Dahm, K. A. M., & Jha, J. C. (2020) · Biology · doi:10.3390/biology10010018 · Cited by 200
“The current management guidelines for T2DM focus on blood glucose stabilization combining education, lifestyle adjustments and pharmacotherapy, whilst monitoring for the aforementioned complications [8].”
BackgroundPharmacotherapy of type 2 diabetes: An update and future directions
DeMarsilis, A. J., Reddy, N., Boutari, C., Filippaios, A., Sternthal, E., Katsiki, N., & Mantzoros, C. S. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155332 · Cited by 184
Wong, E. B., Olivier, S., Gunda, R., Koole, O., Surujdeen, A., Gareta, D., Munatsi, D., Modise, T. H., Dreyer, J., Nxumalo, S., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00176-5 · Cited by 158
Glycemic variability and cardiovascular disease in patients with type 2 diabetes
Martinez, M., Santamarina, J., Pavesi, A., Musso, C., & Umpierrez, G. E. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-002032 · Cited by 155
“12 While HbA1c reflects previous 3-month glycemic control, it does not address short-term glycemic variability (GV) or daily fluctuations in blood glucose levels or hypoglycemic events.”
BackgroundSelf-citationGlycaemic management in diabetes: old and new approaches
Ceriello, A., Prattichizzo, F., Phillip, M., Hirsch, I. B., Mathieu, C., & Battelino, T. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00245-x · Cited by 139
Self-citationA Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Drugs · doi:10.1007/s40265-021-01499-w · Cited by 133
“American College of Endocrinology consensus statement also recommends either a GLP-1RA or SGLT2i as a preferred treatment option (either as first-line or, more typically, second-line treatment after metformin) over alternative options such as a dipeptidyl peptidase-4 inhibitor, a thiazolidinedione (TZD), or a sulfonyl…”
BackgroundKhan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045888 · Cited by 139
Self-citationAroda, V. R., Blonde, L., & Pratley, R. E. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-022-09735-8 · Cited by 135
“In patients with established ASCVD, clinicians should consider using GLP-1RAs or SGLT2is with proven CVD benefit, independent of baseline HbA1c, individualized A1C target, or metformin use [15, 17].”
BackgroundMethodInfluentialSelf-citationKirwan, J. P., Courcoulas, A. P., Cummings, D. E., Goldfine, A. B., Kashyap, S. R., Simonson, D. C., Arterburn, D. E., Gourash, W. F., Vernon, A. H., Jakicic, J. M., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2441 · Cited by 122
Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121
“corresponding to treatment guideline recommendations for most people by the ADA and European Association for the Study of Diabetes (EASD).(84,85) Across the five trials, 81%-97% of participants receiving tir-”
BackgroundMethodInfluentialLi, S., Vandvik, P. O., Lytvyn, L., Guyatt, G. H., Palmer, S. C., Rodriguez-Gutierrez, R., Foroutan, F., Agoritsas, T., Siemieniuk, R. A. C., Walsh, M., et al. (2021) · BMJ · doi:10.1136/bmj.n1091 · Cited by 123
New horizons. A new paradigm for treating to target with second-generation obesity medications
Garvey, W. T. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab848 · Cited by 110
“5% (41) because evidence indicates this will minimize vascular complications such as retinopathy, neuropathy, chronic kidney disease, and CVD risk.”
BackgroundSelf-citationGuidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Kelsey, M. D., Nelson, A. J., Green, J. B., Granger, C. B., Peterson, E. D., McGuire, D. K., & Pagidipati, N. J. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.046 · Cited by 106
Handelsman, Y., Butler, J., Bakris, G. L., DeFronzo, R. A., Fonarow, G. C., Green, J. B., Grunberger, G., Januzzi, J. L., Klein, S., Kushner, P. R., et al. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108389 · Cited by 119
Self-citationD’Andrea, E., Wexler, D. J., Kim, S. C., Paik, J. M., Alt, E. M., & Patorno, E. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.6664 · Cited by 116
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101
Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis
Xie, W., Su, F., Wang, G., Peng, Z., Xu, Y., Zhang, Y., Xu, N., Hou, K., Hu, Z., Chen, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015045 · Cited by 91
“In addition, glinides also having side effects of hypoglycemia (Klein-Schwartz et al., 2016; Garber et al., 2020; Lv et al., 2020).”
BackgroundHandelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., Cherney, D. Z. I., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155931 · Cited by 103
Self-citationNayak, A., Vakili, S., Nayak, K., Nikolov, M., Chiu, M., Sosseinheimer, P., Talamantes, S., Testa, S., Palanisamy, S., Giri, V., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.40232 · Cited by 82
ASMBS position statement on preoperative patient optimization before metabolic and bariatric surgery
Carter, J., Chang, J., Birriel, T. J., Moustarah, F., Sogg, S., Goodpaster, K., Benson-Davies, S., Chapmon, K., & Eisenberg, D. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.08.024 · Cited by 86
“5% for patients without concurrent serious illness and at low hypoglycemic risk) using a combination of lifestyle modification, pharmacotherapy, or surgery [35].”
BackgroundMethodInfluentialCardiovascular Outcomes in Patients With Diabetes and Kidney Disease
Morales, J., & Handelsman, Y. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.052 · Cited by 93
Self-citationOvercoming barriers to implementing new guideline-directed therapies for chronic kidney disease
Nee, R. J., Yuan, C. M., Narva, A. S., Yan, G., & Norris, K. C. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac283 · Cited by 94
Oser, T. K., Hall, T. L., Dickinson, L. M., Callen, E., Carroll, J. K., Nease, D. E., Michaels, L., & Oser, S. M. (2022) · The Annals of Family Medicine · doi:10.1370/afm.2876 · Cited by 72
Konig, M., Riddle, M. C., Colhoun, H. M., Branch, K. R., Atisso, C. M., Lakshmanan, M. C., Mody, R., Raha, S., & Gerstein, H. C. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01386-4 · Cited by 73
Frías, J. P. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1830759 · Cited by 70
The role of sulfonylureas in the treatment of type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999413 · Cited by 79
Rosenfeld, R. M., Kelly, J. H., Agarwal, M., Aspry, K., Barnett, T., Davis, B. C., Fields, D., Gaillard, T., Gulati, M., Guthrie, G. E., et al. (2022) · American Journal of Lifestyle Medicine · doi:10.1177/15598276221087624 · Cited by 71
“, those that cause GI disturbances or cause hypotension, hypoglycemia, myalgia, or fatigue).(87) Intensive lifestyle treatments can quickly reduce the need for medications, and therefore, data from self-monitoring devices can be useful, if available, to guide medication de-escalation.”
BackgroundInfluentialRecent Updates to Clinical Practice Guidelines for Diabetes Mellitus
Yu, J., Lee, S.-H., & Kim, M. K. (2022) · Endocrinology and Metabolism · doi:10.3803/enm.2022.105 · Cited by 65
“TECHNOLOGY IN THE MANAGEMENT OF PERSONS WITH DIABETES MELLITUS The American Association of Clinical Endocrinology (AACE) published an updated guideline for available advanced diabetes technology in 2021 without updating their other guidelines on comprehensive type 2 diabetes management [16,17].”
BackgroundMethodInfluentialDavis, G. M., Peters, A. L., Bode, B. W., Carlson, A. L., Dumais, B., Vienneau, T. E., Huyett, L. M., & Ly, T. T. (2023) · Diabetes Care · doi:10.2337/dc22-1915 · Cited by 69
Ketones: the double-edged sword of SGLT2 inhibitors?
Lupsa, B. C., Kibbey, R. G., & Inzucchi, S. E. (2022) · Diabetologia · doi:10.1007/s00125-022-05815-1 · Cited by 76
Efficacy and safety of semaglutide for weight management: evidence from the STEP program
Amaro, A., Sugimoto, D., & Wharton, S. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2147326 · Cited by 60
“A consensus statement by the American Association of Clinical Endocrinologists and the American College of Endocrinology on the management of T2D recommends that GLP-1RAs should be used cautiously (if at all) in patients with a history of pancreatitis (due to a lack of clinical trial data), and that treatment should b…”
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
“121,126 The cardiac and renal benefits of SGLT2 inhibitors are independent of their glycemic effects and dose, and the class is standard of care for patients with T2D and CKD. 7,30,174 Agents with proven benefits, such as canagliflozin (only in T2D) and dapagliflozin are indicated for patients with T2D with or without…”
InfluentialSelf-citationMilder, D. A., Milder, T. Y., Liang, S. S., & Kam, P. C. A. (2024) · Anaesthesia · doi:10.1111/anae.16306 · Cited by 62
“Current guidelines from the American Association of Clinical Endocrinologists recommend using GLP-1 receptor agonists with caution if they are needed in patients with type 2 diabetes mellitus who have a history ofpancreatitis [53].”
KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
Mottl, A. K., Alicic, R. Z., Argyropoulos, C., Brosius, F. C., Mauer, M. S., Molitch, M. E., Nelson, R. G., Perreault, L., & Nicholas, S. B. (2022) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2021.09.010 · Cited by 62
Self-citationMetformin in Patients With COVID-19: A Systematic Review and Meta-Analysis
Li, Y., Yang, X., Yan, P., Sun, T., Zeng, Z., & Li, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.704666 · Cited by 67
Hamed, K. M., Alosaimi, M. N., Ali, B. A., Alghamdi, A. M., Alkhashi, T., Alkhaldi, S. S., Altowarqi, N. A., Alzahrani, H., Alshehri, A., Alkhaldi, R. K., et al. (2024) · Cureus · doi:10.7759/cureus.68390 · Cited by 94
“Similarly, the AACE/ACE Guidelines propose GLP-1-RAs as the optimum option for combination therapy because their mechanisms of action complement those of other antidiabetic medications [98,100].”
BackgroundOstropolets, A., Elias, P. A., Reyes, M. V., Wan, E. Y., Pajvani, U. B., Hripcsak, G. M., & Morrow, J. (2021) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.120.009115 · Cited by 60
Mitochondrial Dysfunction and Diabetic Nephropathy: Nontraditional Therapeutic Opportunities
Zhang, P., Zhou, M., Guo, J., Zheng, H., Tang, J., Zhang, C., Liu, Y., Liu, W. J., & Wang, Y. (2021) · Journal of Diabetes Research · doi:10.1155/2021/1010268 · Cited by 61
“In 2020, the consensus statement of the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive management algorithm for type 2 diabetes (T2D) mentioned that lifestyle optimization is essential for all diabetic patients, including healthy eating patterns, weight los…”
BackgroundMetformin Benefits: Another Example for Alternative Energy Substrate Mechanism?
Giaccari, A., Solini, A., Frontoni, S., & Prato, S. D. (2021) · Diabetes Care · doi:10.2337/dc20-1964 · Cited by 55
“FromtheUKProspectiveDiabetes Study (UKPDS) (1) onward, virtually all guidelines (2,3) recommendmetformin asfirst-”
BackgroundÇöpür, S., Onal, E. M., Afşar, B., Ortíz, A., van Raalte, D. H., Cherney, D. Z. I., Rossing, P. R., & Kanbay, M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107707 · Cited by 61
Circadian Variation in Efficacy of Medications
Walton, J. C., Walker, W. H., Bumgarner, J. R., Meléndez‐Fernández, O. H., Liu, J. A., Hughes, H. L., Kaper, A. L., & Nelson, R. J. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2073 · Cited by 55
Izzy, M. J., Fortune, B. E., Serper, M., Bhave, N. M., deLemos, A. S., Gallegos-Orozco, J. F., Guerrero-Miranda, C. Y., Hall, S. A., Harinstein, M. E., Karas, M. G., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17049 · Cited by 56
Krishnan, A., Schneider, C. V., Hadi, Y. B., Mukherjee, D., Alshehri, B. Y., & Alqahtani, S. A. (2023) · Diabetologia · doi:10.1007/s00125-023-06057-5 · Cited by 57
“Comparison of the cardiovascular outcomes of GLP-1RAs and SGLT2 inhibitors may help the clinician to select the best personalised treatment approach for patients with type 2 diabetes [38].”
Sarkar, S., & Brown, T. T. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01382-8 · Cited by 59
“The AACE also recommends metformin as a preferred first-line agent, although a GLP-1 receptor agonist or SGLT-2 inhibitor may be considered instead of metformin in patients with chronic kidney disease or ASCVD or at high risk for ASCVD [63].”
BackgroundMonami, M., Candido, R., Pintaudi, B., Targher, G., Mannucci, E., Mannucci, E., Candido, R., Pintaudi, B., Targher, G., Monache, L. D., et al. (2020) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2020.11.031 · Cited by 50
Roles of physical exercise-induced MiR-126 in cardiovascular health of type 2 diabetes
Ma, Y., Liu, H., Wang, Y., Xuan, J., Gao, X. H., Ding, H., Ma, C., Chen, Y., & Yang, Y. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00942-6 · Cited by 52
“The American Association of Clinical Endocrinologists and American College of Endocrinology recommend that each people with T2DM needs individualized exercise prescriptions to exert the maximum impact of exercise on the cardiovascular system [10].”
BackgroundComparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Pedroso Camargos, A., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.05.069 · Cited by 47
Jain, A. B., Ali, A., Gorgojo Martínez, J. J., Hramiak, I., Kavia, K., Madsbad, S., Potier, L., Prohaska, B. D., Strong, J. L., & Vilsbøll, T. (2021) · International Journal of Clinical Practice · doi:10.1111/ijcp.13731 · Cited by 44
Khera, R., Aminorroaya, A., Dhingra, L. S., Thangaraj, P. M., Camargos, A. P., Bu, F., Ding, X., Nishimura, A., Anand, T. V., Arshad, F., et al. (2024) · doi:10.1101/2024.02.05.24302354 · Cited by 46
The role of GLP-1 receptor agonists in managing type 2 diabetes
Nachawi, N., Rao, P. P., & Makin, V. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21110 · Cited by 45
Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy
Docherty, K. F., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1402 · Cited by 44
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“However, these drugs can cause side effects such as hypoglycemia, weight gain, and cardiovascular risk [3].”
BackgroundMacLeod, J., Im, G. H., Smith, M., & Vigersky, R. A. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0365 · Cited by 44
“9,26 In fact, a retrospective analysis of InPen system data indicated 60% of device users required adjustments in their basal insulin dose.”
BackgroundGiugliano, D., Bellastella, G., Longo, M., Scappaticcio, L., Maiorino, M. I., Chiodini, P., & Esposito, K. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14047 · Cited by 43
Artime, E., Romera, I., Díaz‐Cerezo, S., & Delgado, E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01060-8 · Cited by 52
“Of these, blood pressure and lipid control have been regarded as the two most important risk factors for CVD in recent guidelines [8, 9].”
BackgroundOser, T. K., Litchman, M. L., Allen, N. A., Kwan, B. M., Fisher, L., Jortberg, B. T., Polonsky, W. H., & Oser, S. M. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01408-1 · Cited by 43
Pancreas Transplantation: Current Challenges, Considerations, and Controversies
Fridell, J. A., Stratta, R. J., & Gruessner, A. C. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac644 · Cited by 47
Khunti, K., Jabbour, S. A., Cos, X., Mudaliar, S. R. D., Mende, C. W., Bonaca, M. P., & Fioretto, P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14684 · Cited by 45
Alicic, R. Z., & Nicholas, S. B. (2022) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2022.05.003 · Cited by 48
“73 m(2) or lower or UACR of 30 mg/g or higher (no dosage adjustments required), with existing or high risk of ASCVD, or in the presence of metabolic risk factors such as poorly controlled type 2 diabetes and obesity (Table 3(55-64); Figure 2(50,65)).(6,45,47,48,50,66) Furthermore, semaglutide is recommended”
BackgroundZhou, Y., Zhang, Y., Zhang, R., Zhou, Y., Li, N., Wang, M., Tian, H., & Li, S. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001407 · Cited by 41
“Clinical practice guidelines for diabetes are a critical reference for clinicians, and the recommendations in these guidelines rely heavily on evidence from pragmatic RCTs such as EMPA-REG OUTCOME.”
BackgroundInfluentialRole of diabetes in stroke: Recent advances in pathophysiology and clinical management
Bradley, S., Spring, K. J., Beran, R. G., Chatzis, D., Killingsworth, M. C., & Bhaskar, S. M. M. (2021) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3495 · Cited by 44
Cook, K., Adamski, K. N., Gomes, D. A., Tuttle, E., Kalden, H., Cochran, E. K., & Brown, R. J. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab019 · Cited by 43
“5%), and hypertriglyceridemia (defined as ≥200 mg/dL) [34, 35].”
Aroda, V. R., & Eckel, R. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14830 · Cited by 43
Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.02.001 · Cited by 41
Mbara, K. C., Mato, P. E. M., Driver, C., Nzuza, S., Mkhombo, N. T., Gcwensa, S. K., Mcobothi, E. N., & Owira, P. M. O. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173934 · Cited by 36
Nair, R., Mody, R., Yu, M. B., Cowburn, S., Кониг, М., & PREWITT, T. G. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01320-1 · Cited by 39
Wright, E. E., & Aroda, V. R. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1798127 · Cited by 47
Pérez-Belmonte, L. M., Sanz-Cánovas, J., García de Lucas, M. D., Ricci, M., Avilés-Bueno, B., Cobos-Palacios, L., Pérez-Velasco, M. A., López-Sampalo, A., Bernal-López, M. R., Jansen-Chaparro, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.851035 · Cited by 35
Tan, Y. Y., Suan, E., Koh, G. C. H., Suhairi, S. B., & Tyagi, S. (2024) · Archives of Public Health · doi:10.1186/s13690-024-01459-2 · Cited by 35
Lisco, G., Tullio, A. D., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., & Triggiani, V. (2020) · Endocrine · doi:10.1007/s12020-020-02444-9 · Cited by 39
“Gliflozins prescription is increasing over time, also considering a long-term beneficial cardiovascular and renal protection [140, 141].”
BackgroundLorenzatti, A. J., Monsalvo, M. L., López, J. A. G., Wang, H., & Rosenson, R. S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01287-6 · Cited by 34
“Similar aggressive goals are recommended by the American Association of Clinical Endocrinologists and the American College of Endocrinology [20] in patients with diabetes and ASCVD.”
BackgroundResultInfluentialUse of Glucose-Lowering Agents in Diabetes and CKD
Alicic, R. Z., Neumiller, J. J., Galindo, R. J., & Tuttle, K. R. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.09.018 · Cited by 38
Gourdy, P., Schiele, F., Halimi, J., Kownator, S., Hadjadj, S., & Valensi, P. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1227769 · Cited by 35
“Guidelines from the ACC/AHA (15), the AACE/ACE (17), and Diabetes Canada (18), however, recommend metformin as fi rst-line therapy, with GLP-1RAs or SGLT2is administered as an adjunct to metformin in patients with or at high risk for cardiovascular events.”
BackgroundMethodInfluentialThe role of SGLT-2 inhibitors in managing type 2 diabetes
Tsushima, Y., Lansang, M. C., & Makin, V. (2020) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20088 · Cited by 37
Value of Patient-Centered Glycemic Control in Patients with Type 2 Diabetes
Rodríguez‐Gutiérrez, R., Millán-Alanís, J. M., Barrera, F. J., & McCoy, R. G. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01433-0 · Cited by 38
Zhu, M., Li, Y. H., Luo, B., Cui, J., Liu, Y., & Liu, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.861110 · Cited by 45
Yaseen, A., & Lahiri, S. W. (2023) · Clinical Diabetes · doi:10.2337/cd22-0100 · Cited by 38
Amputation Rates and Associated Social Determinants of Health in the Most Populous US Counties
Kassavin, D. S., Mota, L., Ostertag-Hill, C. A., Kassavin, M., Himmelstein, D. U., Woolhandler, S. J., Wang, S. X., Liang, P., Schermerhorn, M. L., Vithiananthan, S., et al. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2023.5517 · Cited by 33
Use of SGLT2 inhibitors during Ramadan: An expert panel statement
Hassanein, M. M., Bashier, A. M., Randeree, H. A., ABOUELMAGD, M. M., Albaker, W. I., Afandi, B. O., Abu-Hijleh, O., Shaltout, I., EI-Sharkawy, M., Dağdelen, S., et al. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108465 · Cited by 35
Liu, T., Liu, J., Wu, Z., Lv, Y., & Li, W. (2021) · Clinical Cardiology · doi:10.1002/clc.23565 · Cited by 34
King, A., & Miller, E. M. (2022) · Clinical Diabetes · doi:10.2337/cd22-0027 · Cited by 34
“5–9% as part of dual or triple therapy with metformin (5).”
BackgroundSinha, B., & Ghosal, S. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01062-6 · Cited by 34
Chen, T., Li, Y., Chen, S., Lin, Y., Sun, C., Chen, D., Mao, C., Michael Shengtao, W. U., Chang, C., Chu, P., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01169-3 · Cited by 32
Liu, T., Wu, Z., Liu, J., Lv, Y., & Li, W. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01297-4 · Cited by 32
“The diagnostic criteria for the classic risk factors, including hypertension (HT) [10] and T2DM [11] were based on authoritative international guidelines.”
MethodSarkar, S., Heyward, J., Alexander, G. C., & Kalyani, R. R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.28782 · Cited by 33
Liu, Z., Yu, S., Jin, X., Sheng, L., Rouzi, M. R. Y., Gao, J., Lü, J., & Lei, T. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s559919 · Cited by 35
Batista, D. V., Vieira, C. A. F. D. A., Costa, T. A., & Lima, E. G. (2020) · Diabetology International · doi:10.1007/s13340-020-00473-3 · Cited by 29
Management of type 2 diabetes with oral semaglutide: Practical guidance for pharmacists
Kane, M. P., Triplitt, C. L., & Solis‐Herrera, C. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa413 · Cited by 41
“Furthermore, AACE/ACE guidance suggests GLP-1RAs as the preferred option, closely followed by a sodium/glucose cotransporter 2 (SGLT2) inhibitor, over other treatment options in this setting.(6) In certain circumstances, for example if metformin is not tolerated or is contraindicated, some GLP-1RAs may be recommended…”
BackgroundInfluentialMaking Diabetes Care Fit—Are We Making Progress?
Ruissen, M. M., Rodríguez‐Gutiérrez, R., Montori, V. M., & Kunneman, M. (2021) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2021.658817 · Cited by 33
“, HbA1c ≤7%) is recommended to achieve diabetes care goals (4, 5).”
BackgroundContinuous glucose monitoring in persons with type 2 diabetes not using insulin
Cowart, K., Updike, W. H., & Franks, R. (2021) · Expert Review of Medical Devices · doi:10.1080/17434440.2021.1992274 · Cited by 27
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 34
Self-citationHbA1C as a Biomarker of Non-alcoholic Fatty Liver Disease: Comparison with Anthropometric Parameters
Masroor, M., & Haque, Z. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2019.00046 · Cited by 41
Metadata
- Authors
- Garber, A. J., Handelsman, Y., Grunberger, G., Einhorn, D., Abrahamson, M. J., Barzilay, J. I., Blonde, L., Bush, M. A., DeFronzo, R. A., Garber, J. R., Garvey, W. T., Hirsch, I. B., Jellinger, P. S., McGill, J. B., Mechanick, J. I., Perreault, L., Rosenblit, P. D., Samson, S., & Umpierrez, G. E.
- Affiliations
- Baylor College of Medicine (US)
- Oakland University (US)
- University of California San Diego (US)
- Beth Israel Deaconess Medical Center (US)
- Kaiser Permanente (US)
- Ochsner Health System (US)
- Cedars-Sinai Medical Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Alabama at Birmingham (US)
- University of Washington (US)
- University of Miami (US)
- Washington University in St. Louis (US)
- Icahn School of Medicine at Mount Sinai (US)
- University of Colorado Anschutz (US)
- University of California, Irvine (US)
- Emory University (US)
- ORCID
- Venue
- Endocrine Practice
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 26
- Issue
- 1
- Pages
- 107-139
- ISSN
- 1530-891X (ISSN-L)
- OpenAlex
- W3004838676
- Cited by
- 598
- References
- 300
- Citations by year
- 2026: 21 · 2025: 41 · 2024: 80 · 2023: 104 · 2022: 146 · 2021: 125 · 2020: 81
- FWCI
- 85.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- Endocrine Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes management, glycemic control, cardiovascular risk, atherosclerotic cardiovascular disease, chronic kidney disease, diabetic ketoacidosis, obstructive sleep apnea, dyslipidemia, obesity, GLP-1 receptor agonists, SGLT2 inhibitors, insulin therapy, continuous glucose monitoring, self-monitoring of blood glucose
- MeSH terms
- Proprotein Convertase 9, Endocrinologists, Algorithms, Blood Glucose, Diabetes Mellitus, Type 2, Humans, United States, Blood Glucose Self-Monitoring, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.